Video

Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more. Read More ›

HER2+ Breast Cancer and CDK4/6 Inhibitors

By Hope S. Rugo, MD

Breast Cancer, Video, SABCS

Conference Correspondent

Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

By Hope S. Rugo, MD

Breast Cancer, Video, SABCS

Conference Correspondent

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

By Hope S. Rugo, MD

Breast Cancer, Video, SABCS

Conference Correspondent

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

By Hope S. Rugo, MD

Breast Cancer, Video, SABCS

Conference Correspondent

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›

Left- vs Right-Sided Colon Cancers

By Eric Van Cutsem, MD, PhD

Colorectal Cancer, Video

Videos

The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy. Read More ›